Financing › Details

MyCartis–SEVERAL: investment, 201409 1st financing round €15m from RMM + Valiance + Biover II


Period Period 2014-09-04
Organisation Money taker MyCartis
Products Product Evalution™ multiplex detection platform
  Product 2 biomarker discovery technology
Index term Index term Pronota–Biocartis: investment, 201409 merger of Pronota with spun-out Swiss Evaluation business of Biocartis to form MyCartis
Person Person Mariën, Rudi (Innogenetics 2007 Chairman + major owner)

Biocartis N.V.. (9/4/14). "Press Release: Biocartis Spins Out Life Sciences Multiplex Platform Evaluation into MyCartis". Mechelen.

Biocartis, an innovative molecular diagnostics company, announced today that it has combined its Swiss Evalution(1)(2) business unit with Belgian-based Pronota NV to jointly form MyCartis(2). MyCartis also completed an EUR 15 million equity round.

Biocartis' Evalution platform, previously known as DMAT, is designed for rapid and cost-effective detection of a broad range of protein and nucleic acid biomarkers, making the system valuable for many clinical and pharmaceutical applications. Pronota has discovered and validated biomarker panels for a range of diseases. As such this content is an ideal match for Biocartis' Evalution platform. MyCartis will continue the development of biomarker panels from the current Pronota laboratories (Technology Park, Ghent), to complement the current activities in Switzerland (Parc Scientifique - EPFL, Ecublens). In order to execute and roll out MyCartis' future ambitions, MyCartis has completed a financing round of EUR 15 million. The capital is subscribed by RMM (Rudi Mariën), Valiance and Biover II (Annie Vereecken). Paul Ladestein is appointed as MyCartis' Chief Executive Officer. Paul joined Biocartis in 2013 as Evalution business unit manager. Being responsible for the establishment and expansion of Luminex EMEIA during the last 11 years, Paul has gained a lot of relevant expertise in serving the life sciences research and diagnostics space with multiplex technologies.

"We believe MyCartis is now all set for the launch of Evalution as a molecular biomarker multiplexing technology this fall. Furthermore, by combining the assets of Evalution with Pronota's biomarker discovery expertise, MyCartis will be able to further expand its offering in the future," said Rudi Pauwels, CEO & Executive Chairman of Biocartis.

"This business combination with Biocartis' Evalution platform offers the potential to capture the full value of Pronota's biomarker assets. With the strong financial backing, MyCartis is well positioned for future growth and success," said Johan Cardoen, Chairman of Pronota.

Paul Ladestein, CEO of MyCartis, added: "We are convinced that Evalution is a very powerful multiplexing detection system bringing unique capabilities that allow laboratories to perform both protein and nucleic-acid biomarker analysis on the same sample, within the same assay plate."


About Biocartis (

Biocartis strives to transform the global diagnostics market by providing instant access to personalized medicine for patients worldwide. The company develops fully integrated and broadly applicable molecular diagnostic solutions that can be used in a wide variety of healthcare settings to provide rapid, high-quality care to patients. Biocartis is working with Janssen Pharmaceutica and Abbott Molecular to develop a range of diagnostic tests in different disease areas. Biocartis has set up in-house commercial scale manufacturing capabilities at its premises in Mechelen (near Brussels). The Idylla™ system and its first oncology assay, the IdyllaTM BRAF Mutation Test, have obtained CE-IVD marking.

About Pronota NV (

Pronota was founded in 2004 and has been developing and commercializing first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including Gimv, LSP and JJDC, and a wide network of renowned key opinion leaders, Pronota has always been committed to making a difference in diagnosis and personalized healthcare.

Pronota has been combined with Biocartis's Evalution business unit to jointly form MyCartis.

About MyCartis (

Operating on the forefront of technology, it is MyCartis' ambition to enable basic and clinical researchers to accelerate biomarker testing through its next generation multiplex biomarker analysis platform. The Evalution platform and its applications provide academic centres, laboratories and pharmaceutical companies with an unprecedented level of biomarker information very quickly, accurately and cost-effectively. The real benefit and practical implementation of personalized medicine can only be achieved through a thorough understanding and clinical validation of the constantly growing number of biomarkers. Together with its partners that share the company's vision, MyCartis has the objective to accelerate innovation in healthcare and help to implement a more molecular- driven medicine that requires high performance molecular testing platforms.

(1) The Evalution platform is currently under development and hence for Life Science Research only.

(2) Evalution and MyCartis are trademark protected

Record changed: 2014-09-15


Picture [LSUK] – The Business Web Portal 650x99px

More documents for MyCartis

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


[iito] Business Intelligence – The Elephants Are Coming 560x113px

» top